delapril (cas 110508-92-4) slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits
-
Add time:08/20/2019 Source:sciencedirect.com
The renin–angiotensin system is an important modulator of arterial blood pressure and inhibitors of the angiotensin-converting enzyme (ACE-Is) and are currently used in the treatment of hypertension. The pleiotropic actions exerted by angiotensin II (AngII) on the functionality of the vessel wall may have pro-atherosclerotic outcomes; evidence for an anti-atherosclerotic effect of ACE-Is has been presented and an antioxidant effect has been attributed to thiol-containing ACE-Is, like Captopril. The present study has been undertaken to investigate the effect of delapril (cas 110508-92-4), a lipophilic ACE-I, on the development of atherosclerosis in cholesterol-fed rabbits. While it did not correct hyperlipidemia, Delapril dose–dependently inhibited the development of atherosclerosis, expressed as aortic area covered by lesions (23.3±4.1, 21.3±2.4 and 18.5±3.3% with Delapril at the daily dose of 5, 10 and 20 mg/kg, respectively, versus 38.2%±6.4 for control animals) and its effect was similar to that of Captopril (14.5±5.1% at the daily dose of 25 mg/kg). Furthermore, Delapril partially and dose–dependently restored endothelium-dependent relaxation, which is impaired in vessels from hypercholesterolemic animals (51.80±12.18, 59.74±5.16, 69.13±8.70 maximal percent relaxation versus 48.26±3.05% for the untreated control and 67.67±6.72% for Captopril-treated animals). An antioxidant mechanism is unlikely to explain this data, since Delapril does not contain thiol groups. These observations suggest that Delapril may represent an effective pharmacological approach for the treatment of atherosclerosis during its early phases.
We also recommend Trading Suppliers and Manufacturers of delapril (cas 110508-92-4). Pls Click Website Link as below: cas 110508-92-4 suppliers
Prev:delapril (cas 110508-92-4) versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy
Next:Congestive heart failure in elderly patients: Controlled study of delapril (cas 110508-92-4) versus captopril) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Safety and efficacy study of delapril (cas 110508-92-4) versus enalapril in patients with congestive heart failure08/22/2019
- Congestive heart failure in elderly patients: Controlled study of delapril (cas 110508-92-4) versus captopril08/21/2019
- delapril (cas 110508-92-4) versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy08/19/2019
- Effects of the fixed combination of manidipine plus delapril (cas 110508-92-4) in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial08/18/2019
- Efficacy and safety of delapril (cas 110508-92-4) plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial08/17/2019
- Effect on the development of ankle edema of adding delapril (cas 110508-92-4) to manidipine in patients with mild to moderate essential hypertension: A three-way crossover study08/16/2019
- Rationale for use of the fixed combination of delapril (cas 110508-92-4) and manidipine in the treatment of hypertension in patients with diabetes mellitus08/15/2019
- delapril (cas 110508-92-4) versus enalapril in patients with congestive heart failure08/14/2019
- Original ArticleDissolution method for delapril (cas 110508-92-4) and manidipine combination tablets based on an absorption profile of manidipine☆08/13/2019